You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Peripheral T-cell lymphoma (PTCL)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Duvelisib, Chidamide
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Jul 27, 2023

First-line Maintenance Treatment of PTCL With Chidamide.

Recruiting
  • PTCL
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jul 23, 2023

HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) Trial (Tipifarnib)

Available
  • HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
  • (no location specified)
Jun 7, 2022

Peripheral T-Cell Lymphoma (PTCL) Trial in Japan, Korea, Republic of (HBI-8000)

Completed
  • Peripheral T-Cell Lymphoma (PTCL)
  • Akita, Japan
  • +22 more
Jun 8, 2022

Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 18, 2023

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)

Enrolling by invitation
  • Peripheral T-cell Lymphoma Targeted Therapy
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023

Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • (no location specified)
Dec 29, 2022

Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

Recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
Jun 15, 2022

Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma
  • Kaohsiung, Taiwan
  • +4 more
Apr 17, 2023

Peripheral T-Cell Lymphoma (PTCL) Trial in United States (Pralatrexate Injection)

Completed
  • Peripheral T-Cell Lymphoma (PTCL)
  • Pralatrexate Injection
  • Rochester, Minnesota
  • +3 more
Jul 23, 2021

Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) Trial in Augusta, Nashville, Houston

Recruiting
  • Mantle Cell Lymphoma
  • +9 more
  • L-Bcl-2 antisense oligonucleotide
  • Augusta, Georgia
  • +2 more
Nov 18, 2022

Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)

Recruiting
  • Peripheral T Cell Lymphoma
  • Azacitidine Injection
  • +6 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022

Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

Active, not recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
  • Yamagata, Japan
    Yamagata University Hospital
Feb 21, 2022

Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL) Trial in United States (KT-333)

Recruiting
  • Non Hodgkin Lymphoma (NHL)
  • +4 more
  • Orange, California
  • +8 more
Nov 29, 2022

Allo-HSCT as First-line Consolidation in High-risk PTCL

Recruiting
  • T Cell Lymphoma
    • Beijing, China
      Peking University People's Hospital
    Jul 31, 2022

    Peripheral T Cell Lymphoma Trial in Harlingen (Belinostat Injection, Pralatrexate Injection, CHOP)

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • Belinostat Injection
    • +3 more
    • Harlingen, Texas
      Valley Cancer Associates
    Oct 16, 2023

    Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (C-BEAM Regimen, BEAM Regimen)

    Recruiting
    • Newly Diagnosed Peripheral T-cell Lymphoma
    • C-BEAM Regimen
    • BEAM Regimen
    • Nanjing, Jiangsu, China
      Hematological Department, People's Hospital of Jiangsu Province
    Jun 27, 2023

    PTCL Trial in Long Beach, New Haven, Charlottesville (Azacytidine, Romidepsin, Belinostat)

    Recruiting
    • PTCL
    • Long Beach, California
    • +2 more
    Mar 1, 2022

    Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

    Not yet recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Peripheral T Cell Lymphoma
    • (no location specified)
    May 30, 2023

    Peripheral T/NK Cell Lymphoma (R/R PTCL) Trial (YY-20394)

    Recruiting
    • Peripheral T/NK Cell Lymphoma (R/R PTCL)
    • Houston, Texas
      MD Anderson Cancer Center
    Oct 19, 2022

    T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL) Trial run by the NCI (IL-15 plus,

    Completed
    Has Results
    • T-Cell Lymphoma Relapsed
    • +4 more
    • IL-15 plus
    • alemtuzumab
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Apr 27, 2022

    Peripheral T-cell Lymphoma Trial in Worldwide (Duvelisib)

    Active, not recruiting
    • Peripheral T-cell Lymphoma
    • Duarte, California
    • +27 more
    May 3, 2022

    Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma Trial in Italy (Daratumumab)

    Active, not recruiting
    • Refractory T-Cell Lymphoma
    • Relapsed T-Cell Lymphoma
    • Bari, Italy
    • +6 more
    Aug 1, 2022